Citadel Advisors’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Citadel Advisors’s Portfolio ALXA Stock Details ALXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-14,600	Closed	-$22K	–	9121
2014 Q4	$22K	Sell	14,600 -5,200	-26%	-$9.28K	﹤0.01%	7751
2014 Q3	$46K	Buy	19,800 +13,600	+219%	+$51.9K	﹤0.01%	6955
2014 Q2	$28K	Sell	6,200 -12,100	-66%	-$52.2K	﹤0.01%	7130
2014 Q1	$81K	Buy	18,300 +12,900	+239%	+$66.1K	﹤0.01%	6378
2013 Q4	$26K	Sell	5,400 -900	-14%	-$4.42K	﹤0.01%	6338
2013 Q3	$32K	Sell	6,300 -18,300	-74%	-$86.1K	﹤0.01%	6014
2013 Q2	$107K	Buy	+24,600	New	+$111K	﹤0.01%	5176

Citadel Advisors's ALXA Position: Q2 2016 in Review

Citadel Advisors sold out of Alexza Pharmaceuticals Inc (ALXA) in Q2 2016, closing a stake of 21,244 shares — an estimated $10K sold.

Citadel Advisors first reported a position in ALXA in Q2 2013 and held it in 8 quarters. The position peaked at $61K in Q3 2014. 0 funds tracked by Wall St. Rank hold ALXA as of Q2 2016.

Citadel Advisors reported no remaining Alexza Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Citadel Advisors sold 21,244 Alexza Pharmaceuticals Inc shares in Q2 2016, an estimated $10K.
Citadel Advisors first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
Citadel Advisors's Alexza Pharmaceuticals Inc position peaked at $61K in Q3 2014.
0 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.